Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTANOL versus GANTRISIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTANOL versus GANTRISIN.
AZO GANTANOL vs GANTRISIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
None Documented
None Documented
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (CrCl >80 mL/min); prolonged to 20-50 hours in CKD (CrCl <30 mL/min); phenazopyridine half-life: 9-11 hours
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic